Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) EPS (Basic) (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed EPS (Basic) for 11 consecutive years, with $0.01 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 101.23% year-over-year to $0.01, compared with a TTM value of -$2.2 through Sep 2025, down 292.98%, and an annual FY2024 reading of $0.93, up 103.84% over the prior year.
  • EPS (Basic) was $0.01 for Q3 2025 at Kiora Pharmaceuticals, up from -$0.54 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $4.67 in Q1 2024 and bottomed at -$45.06 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$4.97, with a median of -$0.9 recorded in 2023.
  • The sharpest move saw EPS (Basic) tumbled 8565.38% in 2021, then skyrocketed 567.0% in 2024.
  • Year by year, EPS (Basic) stood at -$45.06 in 2021, then soared by 90.32% to -$4.36 in 2022, then surged by 49.82% to -$2.19 in 2023, then skyrocketed by 47.49% to -$1.15 in 2024, then skyrocketed by 100.87% to $0.01 in 2025.
  • Business Quant data shows EPS (Basic) for KPRX at $0.01 in Q3 2025, -$0.54 in Q2 2025, and -$0.52 in Q1 2025.